Letters to the Editor: Nicotinic Acetylcholine Receptor Ligands as Potential Targets for Managing Neuropathic Pain Induced by Diabetic Peripheral Neuropathy

Sarah Westlake, Matthew Jones, Krishna D. Sharma, Jennifer Yanhua Xie

Letters to the Editor: Nicotinic Acetylcholine Receptor Ligands as Potential Targets for Managing Neuropathic Pain Induced by Diabetic Peripheral Neuropathy

2022

eNeurologicalSci (Elsevier)

Diabetic peripheral neuropathy
Neurology. Diseases of the nervous system
Nicotinic acetylcholine receptor ligands
Novel pharmacological treatments
RC346-429

English

Diabetic peripheral neuropathy (DPN) is a medical condition that is progressively becoming more prevalent. The underlying cause of DPN is still unknown, although there have been several hypothesized mechanisms. There are current pharmaceutical treatments used to manage the pain, but their efficacy is largely unsatisfactory and are often associated with serious adverse effects. This review will explore the evidence of a new potential target for treating DPN, the ligands for nicotinic acetylcholine receptors (nAChRs), specifically α4ꞵ2 agonists and α9α10 antagonists.

eNeurologicalSci 28, 20220901, 100416

2405-6502/© 2022 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).

PDF